Literature DB >> 9140699

Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol.

J Fang1, G B Baker, P H Silverstone, R T Coutts.   

Abstract

1. Human cytochrome P450 (CYP) isoenzymes expressed in a human cell line were used to elucidate their involvement in the metabolism of haloperidol (HAL). 2. It was found that CYP3A4 catalyzes the metabolism of HAL to HAL 1,2,3,6-tetrahydropyridine (HTP). HTP is further metabolized to HAL pyridinium (HP+) by both CYP3A4 and CYP2D6. 3. CYP3A4 and CYP2D6 are also responsible for the N-dealkylation of HAL. The N-dealkylation of reduced HAL (RH) was observed, which is catalyzed by CYP3A4. In addition, CYP3A4 also catalyzes the oxidation of RH back to HAL. 4. These results are discussed in terms of the metabolic interactions of HAL with other drugs and how this knowledge may be used to reduce the movement disorders induced by HAL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140699     DOI: 10.1023/a:1026317929335

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  14 in total

1.  Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.

Authors:  D C Goff; K K Midha; A W Brotman; M Waites; R J Baldessarini
Journal:  Am J Psychiatry       Date:  1991-06       Impact factor: 18.112

2.  Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.

Authors:  J L Tate
Journal:  Am J Psychiatry       Date:  1989-03       Impact factor: 18.112

3.  Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. I. Excretion and metabolism of haloperidol and nine related butyrophenone-derivatives in the Wistar rat.

Authors:  W Soudijn; I Van Wijngaarden; F Allewijn
Journal:  Eur J Pharmacol       Date:  1967-01       Impact factor: 4.432

4.  Coadministration of fluvoxamine increases serum concentrations of haloperidol.

Authors:  D G Daniel; C Randolph; G Jaskiw; S Handel; T Williams; A Abi-Dargham; S Shoaf; M Egan; A Elkashef; S Liboff
Journal:  J Clin Psychopharmacol       Date:  1994-10       Impact factor: 3.153

5.  MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies.

Authors:  H Rollema; M Skolnik; J D'Engelbronner; K Igarashi; E Usuki; N Castagnoli
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

6.  Determination of 4-(4-chlorophenyl)-4-hydroxypiperidine, a metabolite of haloperidol, by gas chromatography with electron-capture detection.

Authors:  J Fang; G B Baker; R T Coutts
Journal:  J Chromatogr B Biomed Appl       Date:  1996-07-12

7.  Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6.

Authors:  D Young; K K Midha; M J Fossler; E M Hawes; J W Hubbard; G McKay; E D Korchinski
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations.

Authors:  J Fang; J W Gorrod
Journal:  J Chromatogr       Date:  1993-05-05

9.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

Authors:  R F Tyndale; W Kalow; T Inaba
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

10.  Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats.

Authors:  B Subramanyam; H Rollema; T Woolf; N Castagnoli
Journal:  Biochem Biophys Res Commun       Date:  1990-01-15       Impact factor: 3.575

View more
  18 in total

1.  Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

Authors:  K J Aitchison; J Munro; P Wright; S Smith; A J Makoff; C Sachse; P C Sham; R M Murray; D A Collier; R W Kerwin
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.

Authors:  H K Roh; J Y Chung; D Y Oh; C S Park; J O Svensson; M L Dahl; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 3.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 4.  Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2021-01-18       Impact factor: 5.153

Review 5.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

6.  Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients.

Authors:  Eiji Yukawa; Tsuyoshi Hokazono; Miho Yukawa; Ritsuko Ichimaru; Takako Maki; Kanemitsu Matsunaga; Shigehiro Ohdo; Motoaki Anai; Shun Higuchi; Yoshinobu Goto
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol.

Authors:  J G Shin; K Kane; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

8.  Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6.

Authors:  Tohru Ohnuma; Nobuto Shibata; Yoichiro Matsubara; Heii Arai
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

9.  Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?

Authors:  Maju M Koola; Evangelia M Tsapakis; Padraig Wright; Shubulade Smith; Robert W Kerwin Rip; Katie L Nugent; Katherine J Aitchison
Journal:  J Psychopharmacol       Date:  2014-03-04       Impact factor: 4.153

Review 10.  Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

Authors:  Marja-Liisa Dahl
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.